Q1 2017

Filed May 11, 2017 · 10-Q · 40 days after period end · 0001654954-17-004452

Q1 2017 · 10-Q

Revenue—

Net Income

-$1.93M

N/M vs Q1 2016

EPS Diluted

-$0.05

N/M vs Q1 2016

Operating Cash Flow-$50,564N/M

Free Cash Flowderived-$212,562N/M

Same quarter

Metric	Q1 2017	Q1 2016	Q1 2015	Q1 2014
Revenue	—	$5.85M	$5.26M	$3.07M
Net Income	-$1.93M	$255.63K	-$1.03M	-$1.85M
EPS Diluted	-$0.05	$0.01	-$0.03	-$0.05

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Niagen Bioscience, Inc. · CIK 1386570 · Engraved from SEC EDGAR